Aurobindo Pharma Limited has informed the Exchange about submission of copy of Public Announcement pertaining to the Buyback published in newspapers on April 8, 2026
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma has announced a buyback of up to 54,23,728 equity shares (about 0.93% of total outstanding shares) at a price of ₹1,475 per share, for an aggregate value of up to ₹800 crore. The buyback price offers a premium of roughly 10% over the closing price on the board meeting day (April 6, 2026) and around 13–22% over recent volume-weighted average prices on BSE and NSE. The buyback will be executed through the tender offer route using the stock exchange mechanism, with the record date set as April 17, 2026. Funding will come from the company's free reserves and securities premium, and 15% of the buyback is reserved for small shareholders. Several members of the promoter group have indicated their intention to participate in the buyback.
This is a positive development for shareholders — the buyback price sits at a meaningful premium to recent market prices, giving investors a chance to exit at an attractive level, while also potentially boosting earnings per share for remaining holders. Promoter participation signals management confidence in the company's valuation.